Senators demand answers on telehealth platforms from Pfizer and Eli Lilly

Taking stock of the drug industry, from the lab to the medicine chest

October 22, 2024 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Tom Brenner/Pool via AP STAT+ | Senators demand answers on telehealth platforms from Pfizer and Eli Lilly Led by Sen. Dick Durbin of Illinois, senators question if direct-to-consumer website telehealth deals are a new way around old kickback laws. By Katie Palmer STAT+ | Michelle Tarver to lead FDA medical device center Tarver joined the FDA's devices center in 2009, and has temporarily served in the role since the departure of devices head Jeffrey Shuren. By Lizzy Lawrence In a bid to treat their children's rare diseases, these three parents founded companies The founders of Angelman Syndrome Therapeutics, Elpida Therapeutics, Alltrna on starting companies to treat their children's rare diseases. By Anil Oza SARAH GONZALEZ for STAT How a tragic diagnosis sent a journalist on a scientific odyssey Ingrassia explains what he learned about a genetic mutation that runs in his family and that has led to a number of relatives dying at a young age. By STAT Staff

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser